相关实验视频
Updated: Jun 30, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
乌帕达西提尼布在克罗恩病中的治疗方法
Axel Dignass1, Philip Esters1, Cathrin Flauaus2
1Department of Medicine I, Agaplesion Markus Hospital, Frankfurt/Main, Germany.
现在已批准使用口服JAK抑制剂Upadacitinib治疗中度至重度克罗恩病 (CD). 临床研究表明,它在成人患者的诱导和维持治疗中比安慰剂优越.
科学领域:
- 胃肠道学和免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乌帕达西尼布是一种口服,选择性和可逆的Janus激酶 (JAK) 抑制剂.
- 它已获得批准用于治疗成年人中度至重度的活跃克罗恩病 (CD).
- 这项批准标志着在管理炎症性肠病 (IBD) 中取得了重大进展.
研究的目的:
- 评估乌帕达西提尼布在治疗中度至重度活跃克罗恩病中的疗效.
- 评估upadacitinib作为一种新的CD患者口服治疗选择的作用.
主要方法:
- 批准是基于两项诱导研究和一项维护研究.
- 这些研究比较了阿帕达西提尼布治疗与安慰剂.
主要成果:
- 与安慰剂相比,upadacitinib在克罗恩病治疗的诱导和维持阶段都显示出更高的疗效.
- 乌帕达西提尼布代表了首个也是唯一一个被批准用于CD的JAK抑制剂,提供了一种新的作用机制.
结论:
- 乌帕达西尼布的批准扩大了炎症性肠道疾病,特别是克罗恩病的治疗选择.
- 进一步的现实研究和对比比较是必要的,以充分整合upadacitinib到当前的CD治疗算法.
更多相关视频
08:27Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...